Abstract: Efforts to cure diabetes are now focused on restoring a physiologically-regulated population of insulinproducing cells to the patient. A number of animal models of cell regeneration have been employed to study the mechanisms of the process. Islet neogenesis, the regeneration of pancreatic islets from pancreatic stem cells, is arguably the least fraught with barriers to widespread use as a therapy for diabetes. These animal models have led to the description of the reg family of proteins that appear to be related to islet regeneration. Islet neogenesis-associated protein (INGAP) is an initiator of islet neogenesis in animal models and a peptide sequence from INGAP carries the biological activity. INGAP peptide has been shown to stimulate an increase in cell mass in mice, rats, hamsters and dogs. INGAP is also found in the pancreas in human pathological states involving islet neogenesis. The peptide has been tested in human clinical trials, with success being reported. The evidence points to INGAP as a major factor in stimulating islet neogenesis, and, therefore, may play a significant therapeutic role in diabetes.
INTRODUCTION
Diabetes is an increasingly prevalent disease, with estimates of the cost to the U.S. economy of over $130 billion per year. Treatment of diabetes with insulin has changed the nature of the disease from acutely fatal to a chronic state, with complications involving several organ systems as sequelae in 90%+ of patients. Although there are a number of treatments for diabetes, there is as yet no cure.
There are currently 3 major efforts underway to provide a cure for diabetes: 1) islet or pancreas transplant; 2) exogenous stem cell therapies, including bone marrow cells and embryonic stem cells; and 3) regeneration from endogenous pancreatic cells. There is a distinction between the terms "islet regeneration" and "islet neogenesis". Islet regeneration describes an increase in -cell mass in general, regardless of the mechanism, while "islet neogenesis" refers specifically to an increase in -cell mass via the transdifferentiation of adult pancreatic stem cells, putatively found in the ductal epithelium or acinar tissue, into functioning, physiologicallyregulated tissue. This is important, because islet replication is a significant contributor to the physiological maintenance of the overall -cell mass.
The major difficulty with islet or pancreas transplant, aside from issues of immunosuppression, is quantity -providing sufficient numbers of cells or organs to treat the estimated 21 million Americans with diabetes is simply not possible presently. The most successful cadaveric islet transplant method to date for humans, termed the Edmonton Protocol after the location of the original study, requires 2 donor *Address correspondence to this author at the Strelitz Diabetes Center, 855 W. Brambleton Ave., Norfolk, VA 23510, USA; Tel: (757) 446-5986; Fax: (757) 446-5868; E-mail: PittenGL@evms.edu pancreases for each transplant, and most patients have required 2 or more transplants to achieve euglycemia [1] . The islets are administered along with a powerful anti-rejection regimen in order to prolong their survival. Unfortunately only about 10% of these transplant patients remain euglycemic 5 years post-transplant. Further complicating the issue, it has recently been shown that immunotherapy drugs may block survival of the transplanted islets, thereby reducing the efficiency of the procedure [2] .
Exogenous stem cell therapies not only have the barrier of quantity, but also have not yet been proven to consistently differentiate into appropriate, physiologically-regulated pancreatic endocrine tissue. In addition, there is great controversy over ethical issues regarding obtaining sufficient embryonic stem cells to provide a viable alternative source ofcells. Until these problems are overcome, stem cell therapy is not a long term solution.
The most promising in vivo results have been found in islet regeneration studies. There are a number of animal models that exhibit an increase in -cell mass under appropriate stimulation. These models entail both islet neogenesis and islet regeneration by -cell proliferation and have allowed insight into the development and maintenance ofcell mass. This report will show the progression of studies from animal models of islet regeneration commonly used, through studies of regulators of the process and finally the evidence that islet neogenesis-associated protein (INGAP) is of primary importance in the process of islet neogenesis.
ANIMAL MODELS OF PANCREATIC ISLET REGE-NERATION
A number of groups, including our own, have developed animal models of pancreatic islet regeneration in order to study the mechanisms that induce and control increases in -cell mass. Historically, the most common method for induction of an increase in -cell mass in adult animals is the rat partial pancreatectomy model. This method entails destruction of 50-90% of the pancreas, either by manipulation or resection. The remaining pancreas then undergoes a process that includes an increase in endocrine and exocrine tissue. In the partial pancreatectomy model the increase in -cell mass is predominantly due to proliferation of remaining islets rather than de novo generation from stem cells [3] . In addition, there is an increase in inflammatory components due to the pancreatic destruction required. A modification of the partial pancreatectomy model entails dosing the animals with nicotinamide, a poly-(ADP-ribose) synthetase inhibitor, to promote islet regeneration [4] , now dubbed the "Okamoto model". However, the larger islets in the treated animals suggest that the increase is due to -cell proliferation rather than islet neogenesis, and this model does not resolve the issues raised by inflammation of the pancreas in response to pancreatectomy. Therefore, the proteins found in this model are not necessarily specific for islet neogenesis. However, this model led to the discovery of the reg family of proteins [5] [6] [7] .
In the original studies, reg was found predominantly in the pancreas [7] [8] [9] , and its mRNA levels increased in islets induced to proliferate by pancreatectomy and pancreatectomy plus nicotinamide treatment [8, 9] . However, shamoperated rats also showed an increase in reg gene expression. Similar increases in reg gene expression have been seen in studies of other conditions not associated with pancreaticcell growth, for example isolated rat islets accumulate thymidine in parallel with increased reg gene expression, in response to a variety of growth factors [10] . Reg protein has been shown to stimulate pancreatic -cell growth [11] and there was an increase in reg expression in hepatocyte growth factor/scatter factor (HGF/SF)-induced proliferation ofcells [12] . In contrast, implantation of an insulinoma into NEDH rats caused a sharp reduction in reg expression associated with a profound reduction in non-tumor islet size relative to normal controls [13] . Removal of the tumor resulted in rapid -cell proliferation and a large but transient increase in reg mRNA levels in non-islet tissue [6] . Treatment of NOD mice with reg has reduced the incidence of diabetes, supporting the possibility that members of this family of proteins are capable of inducing islet growth [5, 14] .
The reg protein family is a part of a larger group of calcium-dependent carbohydrate binding proteins (C-type lectins), with a wide range of functions. Structural and genetic analysis has led to descriptions of 4 subgroups within the reg protein family [15] (for review see [16] ). They are found mainly in gut or gut-derived tissues including stomach, duodenum and pancreas. Reg proteins promote cell proliferation, and may prevent formation of stones in the ducts of the pancreas. The original reg protein and gene sequence is identical to pancreatic stone protein. Pancreatitis-associated protein is a member of the reg-3 subgroup. Thus, reg proteins appear to have a wide range of functions, both in the pancreas as well as other organs.
Our model of choice has been the cellophane-wrapped pancreas (CW) in the Syrian golden hamster. This model has been well-characterized in the morphological and physiological changes involved in islet neogenesis without the complicating factors of inflammation [17] [18] [19] [20] [21] [22] . An extract prepared from cellophane-wrapped pancreas 10 days after surgery, termed ilotropin, is capable of inducing islet neogenesis and reversing streptozotocin (STZ)-induced diabetes in hamsters [23] . Thus, there are clearly soluble growth factors in the regenerating pancreas that can induce islet neogenesis. In 1997 we identified the gene for INGAP and its protein product using the cellophane-wrapped hamster pancreas model [24] . As part of the report we proposed that a pentadecapeptide sequence carried the biological acitivity, shown in Fig. (1) , and we have since demonstrated that this pentadecapeptide can stimulate an increase in -cell mass in normal animals [25] and reverse streptozotocin-induced diabetes [26] . Clinical studies reported at the annual scientific meetings of the ADA in June 2005 suggested that the peptide may also induce islet neogenesis in patients with both type 1 and type 2 diabetes [27, 28] . INGAP is also a member of the reg family of proteins, sharing the greatest homology with reg-3 in the mouse and reg-3 in humans. Another model for -cell mass manipulation has been developed in Argentina. Force-feeding sucrose to rats or hamsters results in an up-regulation of the -cell mass, allowing investigation of the regulators of the process [29, 30] . The investigators describe an upregulation of INGAP in conjunction with the compensatory increase in -cell mass, suggesting a role for INGAP in islet neogenesis [31] [32] [33] [34] . Of further interest, these investigators examined the effects of sucrose feeding in pregnant hamsters and found a concomitant increase in pancreatic -cell mass and INGAP in the developing fetuses [34] , suggesting that even in utero INGAP plays a role in altering and forming the pancreatic -cell mass.
Based on the INGAP results from previous studies, we have utilized 2 approaches in mouse models of islet neogenesis. Because INGAP peptide is capable of stimulating islet neogenesis, we administered INGAP peptide, representing the biologically active sequence of the INGAP protein [24] , to either normal or STZ-induced diabetic mice. In a small study we have demonstrated that injection of INGAP peptide into STZ-induced diabetic C57BL/6J mice can reverse diabetes by the induction of islet neogenesis [26] . Because STZ destroys such a large percentage of -cells, the most likely mechanism is development from ductal stem cells. INGAP serves as the initiator of a cascade of events that culminates in islet neogenesis, therefore, this model allows for more precise timing around the induction of neogenesis, and may allow for identification of proteins that are involved at specific stages of islet neogenesis.
We have also generated and characterized 2 transgenic mouse lines overexpressing INGAP; one under the control of the insulin promoter, thus expressing INGAP in -cells (INGAP-IP), and the other under the control of the elastase promoter, thus expressing INGAP in acinar cells, the natural source for INGAP (INGAP-EP). Our studies have shown that these animals have a differential resistance to developing hyperglycemia induced by streptozotocin, a -cellspecific toxin that renders normal mice diabetic [35] . INGAP-EP mice have almost 100% protection from STZinduced diabetes. This may be due to the physiological stimulation by endogenous INGAP of a more rapid than normal turnover of -cells in the pancreas in INGAP-EP mice. However, even the INGAP-IP animals show a slowed development of hyperglycemia after STZ injection, indicating a protective role for INGAP with different potencies dependent on the site of production.
INGAP AS A REGULATOR OF PANCREATIC ISLET NEOGENESIS
Studies with the models described have led to the discovery of a number of genes and their protein products as participants in the cascade of events that culminates in the formation of new, physiologically-functioning pancreatic islets from ductal stem cells in adults. Proteins that have been proposed as initiators of islet regeneration include reg [5, 7, 9] , gastrin in combination with EGF [36] [37] [38] , and GLP-1 [39] [40] [41] .
While these growth factors have been shown in at least one study to initiate islet regeneration, their relationship to islet neogenesis is more tenuous. INGAP, however, has been closely associated with islet neogenesis. INGAP has been shown to appear in the pancreatic bud of the mouse at e11, appropriately for a role in new islet formation. Thus, evidence from fetal and adult studies indicate that INGAP plays a role in stimulating the onset of islet neogenesis. In our initial studies we demonstrated that INGAP was capable of stimulating proliferation of pancreatic duct epithelial cells in vitro, a process similar to the initial stages of islet neogenesis in vivo [24] . Subsequent studies have shown that INGAP is expressed in the acinar cells in response to cellophane wrapping and secreted into the lumen of the ducts [42] , where it gains access to the putative stem cells for endocrine neogenesis located in the epithelium lining the ducts.
If INGAP is a trigger for a cascade of molecular and cellular events there must be a number of other proteins that play a role, both in fetal islet development and adult islet regeneration. The best characterized of these are the DNAbinding proteins, e.g. PDX-1. PDX-1 is expressed at 2 different time points in islet development, the first being obligatory for pancreas development and the second at the time of differentiation into insulin-producing -cells [43] [44] [45] . It is revealing that there appears to be an inverse relationship between PDX-1 and INGAP expression, with PDX-1 acting as a repressor of INGAP expression [46] . This might be expected if INGAP is an initiator of islet development, but does not act in an unbridled manner due to a short loop feedback.
Other protein markers of islet development have been shown to play a role in islet development. Neurogenin-3 (NGN-3) is expressed at a stage when the developing cells are neuroendocrine in nature and NGN-3 begins the process of endocrine cell formation [47] [48] [49] . The relationship between INGAP and NGN-3 is not yet known. Circulating factors that are associated with islet regeneration are much less well studied. However, some protein factors, e.g., activin and betacellulin [50] [51] [52] , or EGF with gastrin [53, 54] , have been shown to play a role in initiating islet regeneration. It remains to be determined where these activators fit within the framework of known islet neogenesis initiators.
Although preliminary evidence from the CW model suggests that well-known growth factors are not the primary initiators of neogenesis, there is clearly a role for them in adult islet regeneration. In contrast, there is strong evidence that INGAP is an initiator of islet neogenesis is INGAP.
IN VITRO STIMULATION OF ISLET NEOGENESIS
An extract made from cellophane-wrapped pancreas undergoing islet neogenesis, termed ilotropin, stimulated proliferation of hamster primary duct epithelial cells in culture [55, 56] , the presumed first step in islet neogenesis from adult stem cells. Blocking with antibody directed at the amino acid sequence of INGAP that includes the pentadecapeptide significantly reduced the in vitro proliferative activity of INGAP. Incubation of primary duct epithelial cell cultures with ilotropin for 30 days resulted in the induction of glucagon-positive cells (unpublished data), although complete islets were not formed. Incubation with an extract from control pancreas caused no such differentiation. In another study, stimulation with the INGAP pentadecapeptide of primary duct epithelial cells caused proliferation similar to that of ilotropin [24] . Thus it appears that the bioactivity of ilotropin is due mainly to INGAP.
IN VIVO ISLET NEOGENESIS
We demonstrated that ilotropin could induce islet neogenesis and reverse diabetes when injected i.p. into STZinduced diabetic hamsters [23] . Because INGAP appeared to carry the bioactivity of ilotropin, we tested whether full length recombinant INGAP at doses from 0.1 to10 g/kg/day could reverse STZ-induced diabetes in Syrian golden hamsters. In these studies INGAP stimulated a significant 34 mg/dl drop in blood glucose per log increase in INGAP dose as seen in Fig. (2) . One animal in the control group died, while 7 animals treated with INGAP exhibited blood glucose levels less than 250mg/dl and 3 animals were completely normal. These results were suggestive of an improvement in -cell function. Based on results from other studies the effects are most likely due to islet neogenesis. We also tested whether INGAP peptide could stimulate islet neogenesis in vivo. In a study with normal beagle dogs, INGAP peptide was administered daily for 42 days. There was no toxicity observed at any dose, but INGAP peptide caused a dose-dependent increase in -cell mass, seen in Fig.  (3) that was readily evident in immunofluorescence analysis of insulin as shown in Fig. (4) [25] . There was also a significant increase in insulin gene expression in the INGAPtreated animals that paralleled the calculated changes incell mass [25] .
ISLET NEOGENESIS IN PATHOLOGY
If INGAP is a major factor in inducing islet neogenesis one would expect to find it in instances where new islets are forming. Surgical histology specimens were obtained from patients with confirmed nesidioblastosis secondary to other disease processes. For illustration, we present data from a 66 year old patient with a tumor in the region of the duodenal papilla of Vater. This resulted in partial obstruction of the main pancreatic duct as it opens into the duodenum, similar to the effects of our cellophane wrapping procedure. As can be seen in Fig. (5) the partial obstruction by the tumor caused islet neogenesis (nesidioblastosis) and resulted in a population of pancreatic cells that stained positively on immunohistochemistry for INGAP. Similar changes have been seen in specific patients with tumors, pancreatitis and diabetes [57] .
In another set of patients with non-insulinoma pancreatogenous hypoglycemia as a result of nesidioblastosis, there was a subset that had pancreatic tissue that clearly stained positive for INGAP [58] . The reason that tissues from all the patients did not stain positively for INGAP is not understood, but may be due to some patients being sampled at a later stage of islet development, when the process is well underway and INGAP is no longer required.
Finally, INGAP was detected in a patient who had a pancreatic transplant, but subsequently experienced hypoglycemia as a result of nesidioblastosis in the transplanted organ [59] . Upon partial resection of the pancreas, INGAP was found in pancreatic ducts as predicted by previous in vitro and in vivo studies. Furthermore, the patient continued to have hypoglycemic episodes and upon full resection of the allograft INGAP was still prominently found in the pancreatic tissue. Thus, in several different pathological conditions inducing islet neogenesis, INGAP is readily found, supporting a role for INGAP in islet neogenesis.
INGAP TRANSGENIC MICE
Understanding changes resulting from a sustained neogenic pressure provides another system to identify the factors important in neogenic cascades. Our studies have, in collaboration with NIH, resulted in the generation of INGAP transgenic FVB/N mice that express INGAP, either driven by the rat elastase-1 enhancer 500+8 (EP-INGAP) or the rat insulin promoter (IP-INGAP).
Mice having an exocrine expression of transgenic INGAP, driven by the elastase enhancer (EP-INGAP mice) are resistant to the induction of diabetes (35) . During maturation EP-INGAP mice were euglycemic (blood glucose 128±27 mg/dl and 128±25 mg/dl wild type and EP-INGAP respectively) and gained equivalent age-related weight and pancreas weight (% pancreatic weight at 12 weeks 0.76±0.11 and 0.76±0.09 wild type and EP-INGAP respectively). Both -cell mass and insulin/protein ratios were elevated in EP-INGAP mice and histologically, the islet insulin/glucagon topology was conserved, demonstrated in Fig. (6A) . Expression of INGAP has been screened both by RT-PCR and Northern blotting and demonstrated to be restricted to the pancreas with satellite expression in testes (EP-INGAP) and brain (IP-INGAP) being observed. To generate the transgenic construct INGAP cDNA was cloned downstream of the promoter and upstream of the polyA tail of the rat insulin gene.
Comparison of wild type (non-transgenic littermates) with EP-INGAP mice resulted in no significant phenotype, demonstrated in Fig. (6A) . Mice were euglycemic (blood glucose 128±27 mg/dl and 128±25 mg/dl wild type and EP-INGAP respectively) and gained equivalent age-related weight and pancreas weight (% pancreatic weight at 12 weeks 0.76±0.11 and 0.76±0.09 wild type and EP-INGAP respectively). Histologically the islet architecture of the pancreas was conserved in the EP-INGAP line, though a trend towards increased -cell mass and increased insulin/protein ratio was observed for the EP-INGAP mice. Additionally no gender related changes were observed. Thus the sustained expression of INGAP during development did not adversely affect the gross pancreatic maturation and suggests that the actions of INGAP may have been compensated by receptor down-regulation or some other compensatory mechanism, thus maintaining homeostasis To reveal functional differences between the mouse strains, pancreatic homeostasis was challenged using the diabetogenic agent STZ. In wild type FVB/N mice, a single intraperitoneal injection of 140 mg/kg resulted in elevated fasting blood glucose levels ( 250 mg/dl) within 3 days, which progressed to severe hyperglycemia (fasting blood glucose 550 mg/dl) by day 5 post-injection, illustrated in Fig. (6B) . The hyperglycemia remained elevated ( 550 mg/dl) for the remainder of the14 day study. All the mice in the wild type group (n=6) became hyperglycemic. In marked contrast the EP-INGAP mice did not become hyperglycemic (fasting blood glucose l 250 mg/dl) at any point measured during the study following administration of STZ, also illustrated in Fig. (6B) . The conclusion therefore is that the EP-INGAP mice are resistant to STZ induced hyperglycemia when administered intra-peritoneally at a dose of 140 mg/kg. In order to confirm the diabetic state, blood samples collected at the end of the study were analyzed for insulin content. Consistent with the reported mechanism of action for STZ-induced hyperglycemia, circulating insulin levels in the STZ-dosed wild-type mice were significantly reduced (p<0.001) being just 5% of that detected in non-STZ treated mice. In contrast, EP-INGAP mice, which did not become hyperglycemic following dosing with STZ, had circulating insulin levels which were comparable to insulin levels detected in non-STZ treated EP-INGAP mice. Taken together the data suggest that STZ at 140 mg/kg destroys pancreatic beta cells in wild type FVB/N mice such that the cells fail to produce insulin. However in EP-INGAP transgenic mice, administration of STZ at 140 mg/kg does not result in marked -cell destruction or associated changes in the concentration of circulating insulin and blood glucose.
CAVEATS
Islet neogenesis from endogenous adult pancreatic stem cells is not without its detractors. A lineage tracer study by Dor, et al. using the partial pancreatectomy model suggests that neogenesis does not even occur [60] . Rather, they state that -cell proliferation is responsible for any change incell mass, and there is little to no islet neogenesis occurring in adults. However, regeneration in the partial pancreatectomy model has already been established as at least 90% due to -cell proliferation [3] . In a more recent study using lineage tracing techniques these investigators destroyed -cells using a transgenic model where the -cells are specifically sensitive to doxycycline toxicity. They show again that restoration of -cell mass is predominantly due to -cell proliferation [2] . Using cyclin D2 knockouts, a study by Georgia and Bhushan showed that -cell replication is the major determinant of -cell mass in postnatal life in non-diabetic animals [61] , a result that is to be expected. Other investigators have suggested that small islets near pancreatic ducts are normal, and not the hallmark of islet neogenesis, although it has been shown that duct epithelial cells can be found in a transition state containing both epithelial and endocrine markers under neogenic stimulus [62] . Complicating the interpretation of lineage tracer studies is the observation that islets cultured in vitro can regress to an undifferentiated, duct-like state [63] . These de-differentiated cells can then be induced to differentiate into fully functional islets with the addition of INGAP [64] . If this process could occur in vivo it would make interpretation of lineage tracing studies difficult.
In spite of these studies questioning whether islet neogenesis occurs, there is a body of evidence demonstrating that in response to an appropriate stimulation of the pancreas, one can induce a proliferation of pancreatic duct epithelial cells in the adult pancreas, the generation of PDX-1 and endocrine hormone positive cells within the duct epithelium, and an increase in both the number of smaller, putatively regenerating islets, and the number of islets in close apposition to pancreatic ducts. In addition, investigators have shown that islets can be formed de novo from pancreatic duct epithelium transplanted subcutaneously along with fetal mesenchyme [65, 66] , demonstrating that under the right stimulus adult pancreatic ductal epithelial cells can be induced to differentiate into new endocrine tissue. In support of this notion is the example shown in Fig. (5) of tissues from a 66 year old man with a tumor in the ampulla of Vater, causing obstruction leading to expression of INGAP and "consequent" islet neogenesis. Fig. (7) . Our concept of the progression of islet development from an embryonic stem cell to differentiated islet cells, with factors that are active at the different stages indicated. INGAP appears to act at the same stage as neurogenin-3, although which arises first is unknown.
